Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

3.9K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in <i>Drosophila</i> intestinal metabolism contribute to sexually dimorphic infection outcome and alter gut pathogen virulence.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Streptococcus pyogenes EVs induce the alternative inflammasome via caspase-4/-5 in human monocytes.

EMBO reports·2025
Same author

SOD1 controls neutrophil oxidative burst and microbial killing.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Histone H1 kills MRSA.

Cell reports·2024
Same author

Identification of a Specific Granular Marker of Zebrafish Eosinophils Enables Development of New Tools for Their Study.

Journal of immunology (Baltimore, Md. : 1950)·2024
Same author

ADA2 is a lysosomal deoxyadenosine deaminase acting on DNA involved in regulating TLR9-mediated immune sensing of DNA.

Cell reports·2024

Related Experiment Video

Updated: May 5, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.1K

Second generation S1P pathway modulators: research strategies and clinical developments.

Marc Bigaud1, Danilo Guerini1, Andreas Billich1

  • 1Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland.

Biochimica Et Biophysica Acta
|November 19, 2013
PubMed
Summary

Fingolimod, the first oral treatment for Multiple Sclerosis (MS), works by modulating S1P1 receptors to reduce CNS inflammation and neurodegeneration. Research explores next-generation therapies targeting sphingolipid pathways for improved MS treatment.

Keywords:
FingolimodImmunomodulatorS1P modulatorS1P1

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Related Experiment Videos

Last Updated: May 5, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.1K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Cell Biology

Background:

  • Multiple Sclerosis (MS) is a chronic CNS autoimmune disease characterized by demyelination and neurodegeneration.
  • Traditional MS treatments often require injection delivery.
  • Fingolimod (Gilenya) was the first oral MS therapy approved in 2010.

Purpose of the Study:

  • To review the mechanisms of action for fingolimod in MS.
  • To discuss the development of novel sphingolipid receptor modulators for MS.
  • To explore alternative therapeutic strategies targeting the S1P pathway.

Main Methods:

  • Review of preclinical and clinical data on fingolimod.
  • Analysis of S1P receptor modulation and its effects on lymphocytes and astrocytes.
  • Discussion of emerging therapeutic approaches including antagonists, lyase inhibitors, and antibodies.

Main Results:

  • Fingolimod down-modulates S1P1 receptors, preventing T cell entry into the CNS and reducing astrogliosis.
  • Evidence suggests fingolimod promotes nerve conduction recovery and remyelination.
  • Clinical trials show fingolimod reduces inflammatory markers and brain atrophy in MS patients.

Conclusions:

  • Fingolimod offers a significant oral treatment option for MS by targeting S1P receptor pathways.
  • Ongoing research focuses on developing selective S1P receptor modulators for enhanced efficacy and safety.
  • The field is advancing with diverse strategies to combat MS pathogenesis.